US Senate Majority Leader and Other Senators Urge DEA to “Promptly Finalize” Marijuana Rescheduling

A group of prominent senators have sent a letter to the Biden Administration urging them to promptly reschedule marijuana.

Yesterday, U.S. Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chair Ron Wyden (D-OR), along with Senators Cory Booker (D-NJ), Tina Smith (D-MN), Ben Ray Luján (D-NM), Patty Murray (D-WA), and Kirsten Gillibrand (D-NY) sent a letter to Attorney General Merrick Garland and DEA Administrator Anne Milgram, expressing their strong support for the Drug Enforcement Administration’s (DEA) proposal to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).

“We write to express support for the Drug Enforcement Administration’s proposal to transfer marijuana from schedule I to schedule III of the Controlled Substances Act (“CSA”)”, states the lett. “The proposed rule to reclassify marijuana to schedule III recognizes the medical benefits of marijuana, will improve access for studying the health effects of short and long-term cannabis use, and will provide relief to cannabis businesses that continue to navigate a patchwork regulatory system to conduct legal business”.

They continue; “On October 6, 2022, President Biden directed the Secretary of Health and Human Services and the Attorney General to initiate the administrative review process to review expeditiously how marijuana is scheduled under federal law. In 2023, after undertaking the eight-factor analysis required under the CSA, HHS found, and recommended to DEA, that marijuana did not meet the criteria to continue classification as a Schedule I substance and that it be transferred to Schedule III.

HHS conducted a two-part inquiry to consider the Current Accepted Medical Use (CAMU) of marijuana, and concluded that it has a CAMU to treat pain, anorexia, nausea, vomiting, among other ailments, without posing ‘unacceptably high safety risks.’”

The letter states that “Rescheduling presents significant benefits to public health, research, business, and Americans harmed by the lasting effects of our punitive drug policies. It will also bolster cannabis-related businesses, many of which are owned by people criminalized for marijuana offenses, opening them up to critical investment opportunities.”

The Senators also emphasized the need to pass comprehensive legislation, like the Cannabis Administration and Opportunity Act (CAOA), to fully end federal prohibition and establish a federal regulatory framework that prioritizes restorative justice and public health. Senators Booker, Schumer, and Wyden led the reintroduction of the CAOA earlier this year.

“Rescheduling is not the panacea to undoing the harms caused by decades of marijuana prohibition, but it is a step toward addressing the policies that have devastated communities across the country. Cannabis should be entirely de-scheduled. Yet, we recognize and appreciate DEA’s effort to address the flaws in our current marijuana policy by using its authority under the CSA and following the scientific and medical evidence to reschedule marijuana as a Schedule III drug. We urge DEA to finalize the rule,” the Senators concluded.

Thank you for reading The Marijuana Herald! You can find more news stories by clicking here, and you can signup for our newsletter by clicking here

 

 

More articles from The Marijuana Herald.

Florida Lawmaker Files Bill to Ban Public Marijuana Smoking Across the State

Florida Lawmaker Files Bill to Ban Public Marijuana Smoking Across the State

Massachusetts Cannabis Regulators Expected to Finalize Long-Delayed Social Consumption Rules by Christmas

Massachusetts Cannabis Regulators Expected to Finalize Long-Delayed Social Consumption Rules by Christmas

Curaleaf Appeals $31.8 Million Judgment in Michigan Contract Fight With Hello Farms

Curaleaf Appeals $31.8 Million Judgment in Michigan Contract Fight With Hello Farms

Arizona Marijuana Tax Revenue Reached $20.7 Million in October, $233.2 Million Year-to-Date in 2025

Arizona Marijuana Tax Revenue Reached $20.7 Million in October, $233.2 Million Year-to-Date in 2025

New Jersey Bill Would Expand Dispensary Access, Loosen CRC Restrictions, and Strengthen Enforcement Against Illegal Operators

New Jersey Bill Would Expand Dispensary Access, Loosen CRC Restrictions, and Strengthen Enforcement Against Illegal Operators

THC Strengthens Brain-Based Pain Filtering in Fibromyalgia, New Clinical Trial Finds

THC Strengthens Brain-Based Pain Filtering in Fibromyalgia, New Clinical Trial Finds

Hemp Shows Strong Antiviral Activity Against Japanese Encephalitis Virus

Hemp Shows Strong Antiviral Activity Against Japanese Encephalitis Virus

Higher Light Intensity During Flowering Found to Boost CBD Production in Hemp

Higher Light Intensity During Flowering Found to Boost CBD Production in Hemp

Psilocybin Shows Potential to Improve Long-Term Effects of Repetitive Brain Injuries Linked to Intimate Partner Violence

Psilocybin Shows Potential to Improve Long-Term Effects of Repetitive Brain Injuries Linked to Intimate Partner Violence

Florida Campaign to Legalize Recreational Cannabis Has Submitted 675,000 Verified Signatures for 2026 Initiative

Florida Campaign to Legalize Recreational Cannabis Has Submitted 675,000 Verified Signatures for 2026 Initiative

Ohio Marijuana Market Generated $1.25 Billion in Sales Since Adult-Use Launch in August 2024, Producing $164 Million in Tax Revenue

Ohio Marijuana Market Generated $1.25 Billion in Sales Since Adult-Use Launch in August 2024, Producing $164 Million in Tax Revenue

Study: Medical-Grade THC Vape Delivers Precise Microdoses, While Retail Pens Hit Hard but With Unstable Output

Study: Medical-Grade THC Vape Delivers Precise Microdoses, While Retail Pens Hit Hard but With Unstable Output

Arkansas Medical Marijuana Program Reaches 112,760 Registered Patients

Arkansas Medical Marijuana Program Reaches 112,760 Registered Patients

New Mexico Marijuana Sales Reach $475 Million in 2025, Nearly $2 Billion All-Time

New Mexico Marijuana Sales Reach $475 Million in 2025, Nearly $2 Billion All-Time

Curaleaf Reports $320 Million in Q3 Revenue, 158 Dispensaries Across the U.S.

Curaleaf Reports $320 Million in Q3 Revenue, 158 Dispensaries Across the U.S.

Aurora Cannabis Reports $90.4 Million in Fiscal Q2 2026 Revenue, Driven by Record Medical Sales

Aurora Cannabis Reports $90.4 Million in Fiscal Q2 2026 Revenue, Driven by Record Medical Sales

Trulieve Reports $288 Million in Q3 Revenue and $173 Million Year-to-Date Free Cash Flow

Trulieve Reports $288 Million in Q3 Revenue and $173 Million Year-to-Date Free Cash Flow

Study: CBD Shown to Suppress Growth Pathways in Aggressive Breast Cancer Cells

Study: CBD Shown to Suppress Growth Pathways in Aggressive Breast Cancer Cells